Navigation Links
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
Date:11/8/2007

re assessed for all patients at both the three- and six-month visits.

Patients who completed the full six-months of treatment in Study FMS-031 were eligible to enroll in a multi-center, dose-blinded, extension study designed to evaluate durability of response up to one year. A total of 449 patients were either maintained at 200 mg/day (n=209) or re-randomized to 100 mg/day (n=48) or 200 mg/day (n=192) for an additional six months. Efficacy assessments included change in pain, as measured using a paper visual analog scale, and multidimensional symptomatic improvements, as measured using the Fibromyalgia Impact Questionnaire and PGIC.

Data Highlights

Results reported below are based on observed cases, which include only patients who were evaluable at the landmark visit. In study MLN-MD-02, there were 713 evaluable patients for the fibromyalgia syndrome and pain analyses (n=236 for 100 mg, n=215 for 200 mg, and n=262 for placebo).

In study FMS-031, at the three-month visit there were 549 evaluable patients for the syndrome analysis (n=134 for 100 mg, n=259 for 200 mg, and n=156 for placebo), and 553 evaluable patients for the pain analysis (n=135 for 100 mg, n=260 for 200 mg, and n=158 for placebo). At the six-month visit there were 488 evaluable patients for the fibromyalgia syndrome analysis (n=120 for 100 mg, n=229 for 200 mg, and n=139 for placebo), and 491 evaluable patients for the fibromyalgia pain analysis (n=121 for 100 mg, n=230 for 200 mg, and n=140 for placebo).

Composite responder rates for fibromyalgia syndrome (pain, PGIC, and SF-36 PCS)

-- A statistically significant number of patients treated with milnacipran

during Study MLN-MD-02 met the composite syndrome responder criteria

(25% and 26% for the milnacipran 100 mg and 200 mg groups,

respectively) compared to patients treated with placebo (13%).

-- A statistically significant number of patients treated with milnacipran

durin
'/>"/>

SOURCE Forest Laboratories, Inc. and Cypress Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
2. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
3. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
4. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
5. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
11. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... BETHESDA, Md., May 14 Spherix Incorporated (Nasdaq: SPEX ), ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today ... Company Highlights , , ... Created a wholly owned subsidiary, Biospherics Incorporated, ...
... SAN DIEGO, May 14 TargeGen, Inc. today ... a multi-center clinical trial of TG101348, an oral, ... patients with myelofibrosis on May 7, 2009.(Logo: ... conducted at six centers in the USA. The ...
Cached Medicine Technology:Spherix Reports First Quarter 2009 Earnings 2Spherix Reports First Quarter 2009 Earnings 3Spherix Reports First Quarter 2009 Earnings 4Spherix Reports First Quarter 2009 Earnings 5Spherix Reports First Quarter 2009 Earnings 6Spherix Reports First Quarter 2009 Earnings 7
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... to have beneficial effects as sleep aids and calming remedies, which help to improve ... the result of a great deal of research in the field of regenerative medicine ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Kathleen Kall has been promoted from Administrative assistant to Executive Assistant ... communication, you’ll interact with a proven professional, focused on your goals. Kathleen ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2
... checking the profits and safety of the drugs the ... monitor that only branded and quality medicines are sold ... Pharmaceutical Price Regulation Scheme [PPRS] is a voluntary organization ... and quality of the drugs every 5 years. It ...
... to bare metal stents, placement of stents that ... the artery re-narrowing nine months following angioplasty for ... an article in the September 14 issue of ... of atherosclerotic coronary artery disease, according to background ...
... up with a disaster-planning guide to help the people ... tropical storms, hurricanes, tidal waves and cyclones. ,No ... vulnerable to some sort of natural disaster such as ... terrorist attacks are also possible. Both natural disasters and ...
... findings of a recent study researchers say that certain chemicals ... to help current and former smokers ward off development of ... ,Researchers say their study provides significant insight into ... which the process can be slowed down after exposure has ...
... over the increasing malfunction of heart devices, which they ... and 2002. ,The Food and Drug Administration (FDA) ... and heart-device manufacturers recently, which found that 4,225 defibrillators ... defibrillators failed in the previous 10 years, reports online ...
... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
Cached Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Stents That Release Medication To Check Artery Narrowing 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2
... 6 is an enzyme immunoassay (EIA) test ... various specific nuclear antigens (SS-A, SS-B, RNP/Sm, ... is used as an aid in the ... connective tissue disease (MCTD), Sjgren's syndrome and ...
The 8500 is an extremely reliable portable pulse oximeter, requiring no periodic maintenance or calibration....
The PalmSAT® 2500 series are small, yet versatile digital pulse oximeters for accurate assessment of blood oxygen saturation and pulse rate. Choose alarm or non-alarm versions for your portable ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: